Business Standard

Analysts' corner

Dr Reddy's Labs & Indraprastha Gas

Read more on:    Indraprastha Gas | Dr Reddys Labs
Related News

DR REDDY’S LABS
Reco price: Rs 1,709;
Target price: Rs 1,950
Dr Reddy’s (DRRD) has filed an abbreviated new drug application for singulair granules oral formulation, used for treatment of asthma in children. Innovator Merck has sued DRRD for infringement of a patent on this, which expires in October 2022. This product has $80 million annual sales in the US. DRRD can launch earliest in September 14, after expiry of a 30-month stay on generic launch. Mylan and Teva could be the first to file on this product. Overweight.

HSBC Global Research


Reco price: Rs 346;
Target price: Rs 426
The Petroleum and Natural Gas Regulatory Board (PNGRB) has issued an order on network rates and compression charge for Indraprastha Gas (IGL);. Against IGL’s proposed Rs 7.8/scm of network rate and compression charge, the PNGRB has allowed a mere Rs 3.1/scm, a decline of Rs 4.7/scm. Even after allowing for a marketing margin over and above this (the quantum of which, however, is uncertain), the order comes as a significant negative surprise, leading to a potential downside of 45-65 per cent to Citigroup’s Ebitda. Under this scenario, IGL will struggle to make even normative returns on the capital it has invested in the business. Maintain buy.

Citigroup

Read more on:   
|

Read More

Axis Bank: Concerns reflect in valuations

Axis Bank posted good set of numbers for the quarter ended 31st March 2012, beating the consensus estimates. Higher than expected growth in interest ...

Quick Links

 

Market News

Biocon gains on robust Q4 earnings

Standalone net profit for the fourth quarter surged 126.5% to Rs 86.74 crore

Cairn India slides on disappointing guidance

The stock has dipped 5% to Rs 336 on the National Stock Exchange.

Pre-market: Lower opening seen on weak Asian cues

Markets are likely to open marginally lower amid weak Asian cues

Rich investors borrowed Rs 4,000 cr to bet on Wonderla public offer

Break-even only if IPO lists at 25%-plus premium

Challenges continue for ACC

Both net sales and Ebitda for the March quarter were lower than Street estimates

Back to Top